van der Heiden Pim L J, de Boer Renate, van der Steen Dirk M, Kester Michel G D, van der Hoorn Menno W A G, Haarman Wilmy M E, Barnby-Porritt Helen E, Fry Jeremy W, Napper C E, Marijt Erik W A, Willemze Roel, Falkenburg J H Frederik, Heemskerk Mirjam H M
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
J Virol. 2009 Jul;83(14):7361-4. doi: 10.1128/JVI.02662-08. Epub 2009 Apr 22.
To study the role of CD8 T cells in the control of varicella-zoster virus (VZV) reactivation, we developed multimeric major histocompatibility complexes to identify VZV-specific CD8 T cells. Potential HLA-A2 binding peptides from the putative immediate-early 62 protein (IE62) of VZV were tested for binding, and peptides with sufficient binding capacity were used to generate pentamers. Patients with VZV reactivation following stem cell transplantation were screened with these pentamers, leading to the identification of the first validated class I-restricted epitope of VZV. In 42% of HLA-A2 patients following VZV reactivation, these IE62-ALW-A2 T cells could be detected ex vivo.
为研究CD8 T细胞在水痘带状疱疹病毒（VZV）再激活控制中的作用，我们开发了多聚体主要组织相容性复合体以鉴定VZV特异性CD8 T细胞。对来自VZV假定的立即早期62蛋白（IE62）的潜在HLA - A2结合肽进行结合测试，并使用具有足够结合能力的肽来生成五聚体。用这些五聚体对干细胞移植后发生VZV再激活的患者进行筛查，从而鉴定出首个经过验证的VZV I类限制性表位。在VZV再激活后的HLA - A2患者中，42%可在体外检测到这些IE62 - ALW - A2 T细胞。
